S53P4 Bioactive Glass Granules for the Management of Bone, Joint, and Related Soft-Tissue Infections: An Updated Review

Simple item page
dc.contributor.authorAngthong, Chayanin
dc.contributor.authorVichayabhai, Tyler
dc.contributor.authorTatiya-Apitham, Phurin
dc.date.accessioned2026-08-06T10:51:45Z
dc.date.available2026-08-06T10:51:45Z
dc.date.issued2025-07-31
dc.description.abstractBACKGROUND: Bioactive glass S53P4 has drawn increasing interest for its use in managing chronic osteomyelitis, infected non-unions, and related soft-tissue infections. This review synthesizes clinical evidence with emphasis on comparative studies versus autologous bone grafts, allografts, and antibiotic carriers. MATERIAL AND METHODS: We performed a comprehensive search of PubMed, EMBASE, and Scopus (January 2013 to September 2025) that identified human clinical studies reporting outcomes of S53P4 in bone, joint, and related soft-tissue infections. Search terms combined 'S53P4' OR 'bioactive glass' with 'osteomyelitis', 'bone infection', 'infected non-union', 'joint infection', and 'dead space management'. The data were screened, reviewed, extracted, and analyzed in accordance with the PRISMA guideline. RESULTS: Across heterogeneous cohorts, infection eradication rates typically range from 80-95% with S53P4, bone healing is comparable to autograft, and complication rates are low. Comparative data suggest non-inferior infection control and bone consolidation relative to autograft/antibiotic-polymethylmethacrylate, with potential advantages for one-stage care and reduced length of stay. CONCLUSION: S53P4 bioactive glass provides infection control and bone regeneration outcomes comparable to autograft and selected antibiotic carriers in chronic osteomyelitis and infected non-unions. Its antimicrobial and osteoconductive properties enable effective one-stage treatment in many cases, with a favorable safety profile and potential cost savings. High-quality randomized trials remain limited, but current evidence supports S53P4 as a viable, cost-effective adjunct in orthopedic infection surgery.
dc.identifier.citationOrtopedia Traumatologia Rehabilitacja, 27(4), 143-148, 2025
dc.identifier.doi10.5604/01.3001.0055.6433
dc.identifier.issn20844336
dc.identifier.other2-s2.0-105030895582
dc.identifier.urihttps://dspace.kmitl.ac.th/handle/123456789/17138
dc.sourceOrtopedia Traumatologia Rehabilitacja
dc.subjectbioactive glass
dc.subjectbone
dc.subjectbone graft
dc.subjectjoint
dc.subjectosteomyelitis
dc.subjectS53P4
dc.subjectsoft-tissue infection
dc.titleS53P4 Bioactive Glass Granules for the Management of Bone, Joint, and Related Soft-Tissue Infections: An Updated Review
dc.typeReview

Files

Collections

Research